Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Leerink Partners Upgrades Eli Lilly to Outperform, Raises Price Target to $1104

Author: Benzinga Newsdesk | November 10, 2025 06:31am
Leerink Partners analyst David Risinger upgrades Eli Lilly (NYSE:LLY) from Market Perform to Outperform and raises the price target from $886 to $1104.

Posted In: LLY


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist